Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating Costs and Expenses:
General and administrative	$ 2,090	$ 2,426
Research and development	6,059	8,155
Total Operating Costs and Expenses	8,149	10,581
Loss from Operations	(8,149)	(10,581)
Other Income (Expense):
Change in fair value of warrant liability	5,090	(498)
Interest income	1	1
Total Other Income (Expense)	5,091	(497)
Net Loss	(3,058)	(11,078)
Net Loss Attributable to Non-controlling Interest	(212)	(233)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (2,846)	$ (10,845)
Net Loss Per Share - Basic and Dilutive	$ (0.02)	$ (0.12)
Weighted average number of shares outstanding during the period - Basic and Dilutive	117,447,260	90,826,752